Biotinylated Human GUCY2C Protein (C-6His-Avi)

Name: Biotinylated Human GUCY2C Protein (C-6His-Avi)
Brand: Beta LifeScience
SKU: BL-2813NP
Price: 679.0 USD
Availability: InStock

BL-2813NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Avi-tagged proteins, Biotinylated proteins, Featured biotinylated protein molecules, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Biotinylated Recombinant Human Guanylyl Cyclase C is produced by our Mammalian expression system and the target gene encoding Ser24-Gln430 is expressed with a 6His tag and a Avi tag at the C-terminus.
Accession	P25092
Synonym	Heat-stable enterotoxin receptor; GUCY2C; STA receptor; hSTAR; Guanylyl cyclase C; GC-C; Intestinal guanylate cyclase; GUC2C; STAR
Gene Background	GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family. GUCY2C cell surface expression is confined to luminal surfaces of the intestinal epithelium and a subset of hypothalamic neurons. The inaccessibility of GUCY2C in the apical membranes of polarized epithelial tissue, due to subcellular restriction of GUCY2C, creates a therapeutic opportunity to target metastatic lesions of colorectal origin which have lost apicalbasolateral polarization without concomitant intestinal toxicity. And that CAR-T cells targeting murine GUCY2C were effective against colorectal cancer metastatic to lung in the absence of intestinal toxicities. Human GUCY2C-targeted CAR that could potentially be employed in patients with GUCY2C-expressing gastrointestinal malignancies.
Molecular Mass	48.6 KDa
Apmol Mass	65-110 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Receptor for the E.coli heat-stable enterotoxin (E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GC-C). Also activated by the endogenous peptides guanylin and uroguanylin.
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Note=The 145 kDa plasma membrane form of GC-C contains sialic acid and galactose residues, while a differencially glycosylated 130 Kda form is a high mannose form that is resident in the endoplasmic reticulum and may serve as the precursor for the cell surface form.
Protein Families	Adenylyl cyclase class-4/guanylyl cyclase family
Database References	HGNC: 4688 OMIM: 601330 KEGG: hsa:2984 STRING: 9606.ENSP00000261170 UniGene: Hs.524278
Associated Diseases	Diarrhea 6 (DIAR6); Meconium ileus (MECIL)

Gene Functions References

High Expressions of guanylyl cyclase C is associated with rectal cancer. PMID: 28418917
The findings support that the activating mutation in GUCY2C creates an intestinal environment with a major influence on the microbiota, which could contribute to the increased susceptibility to inflammatory bowel disease in patients with Familial GUCY2C diarrhea syndrome. PMID: 28902124
the expression of GCC is maintained throughout the process of tumor progression and formation of metastatic disease. PMID: 29261789
To investigate gut motility and hormones before and after a meal in Familial GUCY2C diarrhea syndrome patients and compare with healthy controls PMID: 28957388
Mutations in GUCY2C indicate a role for this receptor in the pathogenesis of sporadic Congenital secretory diarrhea. PMID: 25994218
these data support Ad5-GUCY2C-PADRE as a safe and effective vaccination strategy in preclinical models and position Ad5-GUCY2C-PADRE for Phase I clinical testing in colorectal cancer patients. PMID: 27903079
Familial GUCY2C diarrhoea syndrome is caused by an activating mutation in the GUCY2C gene, which causes impaired contractility and fluid stagnation in the small bowel PMID: 27338166
Findings show how caloric suppression of the guanylin-GUCY2C signaling axis links obesity to negation of a universal tumor suppressor pathway in colorectal cancer. PMID: 26773096
Data show that individuals affected with meconium ileus (MI) had either homozygous or compound heterozygous variants in enterotoxin receptor GUCY2C. PMID: 25370039
High guanylyl cyclase C expression is associated with colon cancer recurrence. PMID: 24919572
Transmission disequilibrium tests (TDT), case-control studies and quantitative analyses indicated association between GUC2C with Attention-deficit/hyperactivitydisorder and its core symptoms. PMID: 25064385
Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21. PMID: 24217248
GUCY2C signaling constitutes a direct link between the initiation of colorectal cancer and the induction of its associated desmoplastic stromal niche. PMID: 24085786
Data show that lower survival (OS) and disease-free survival (DFS) rates were significantly associated with guanylate cyclase C (GCC) and CK20 mRNA levels. PMID: 23150200
Interaction with VIP36 is dependent on glycosylation at the same sites that allow GC-C to fold and bind ligand. PMID: 23269669
GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity PMID: 22384056
Mutations in GUCY2C were associated with the Meconium ileus phenotype. downregulation of GUCY2C leads to a cystic fibrosis-like intestinal phenotype. PMID: 22521417
We identified a heterozygous missense mutation (c.2519G-->T) in GUCY2C in all family members with familial diarrhea syndrome. PMID: 22436048
High guanylyl cyclase C is associated with colon cancer. PMID: 21533822
Data suggest that monitoring the peripheral blood GCC expressions may allow employing different treatment options to metastatic CRC patients. PMID: 21901559
Lymph nodes (range: 2-159) from 291 prospectively enrolled node-negative colorectal cancer patients were analyzed by histopathology and GUCY2C quantitative RT-PCR. PMID: 21307149
Longer survival was associated with hypomethylation at specific CpG sites (e.g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e.g. TMCO5, PTPRN and GUCY2C). PMID: 21577013
A novel PDZ protein regulates the activity of guanylyl cyclase C, the heat-stable enterotoxin receptor. PMID: 11950846
guanylyl cyclase c is ectopically expressed in primary and metastatis adenocarcinoma of the esophagus and stomach PMID: 12163327
SH3 domain -mediated protein-protein interaction with the catalytic domain of guanylyl cyclase C inhibited the cyclase activity and might be pivotal for the desensitization phenomenon of the guanylyl cyclase C receptor PMID: 12649275
gelatinolytic activity of GCC in colorectal tumor tissues may facilitate the hepatic metastatic process in the steps after intravasation but not during or before intravasation PMID: 14581363
a novel role for glycosidic modification of GC-C during its biosynthesis, in imparting subtle conformational changes in the receptor that allow for ligand-mediated activation and perhaps regulation of basal activity PMID: 14748740
Lack of guanylyl cyclase c expression assoeciated with significant reduction in adenomas in Apc(Min/+);Gucy2c(-/-) mice PMID: 15825168
Transformation associated with reflux at the gastroesophageal junction reflects activation by bile acid and acid of a transcriptional program involving NF-kappaB and Cdx2, which mediate intestinal metaplasia and ectopic expression of GC-C. PMID: 16618413
This validated assay is being applied to approximately 10,000 lymph nodes in a prospective trial to define the sensitivity of Guanylyl cyclase C(GCC) qRT-PCR for staging patients with colorectal cancer. PMID: 16899600
docking of the c-src SH2 domain to phosphorylated GC-C results in colocalization and further activation of c-src. PMID: 19620276
the role of the linker region in receptor guanylyl cyclases PMID: 19648115
GCC is a specific marker for differentiating primary and secondary metatstatic ovarian mucinous neoplasms. PMID: 19694825
Results suggest that GUCY2C quantitative reverse transcriptase (qRT)-PCR can be used to detect occult lymph node metastases in pN0 colorectal cancer patients. PMID: 19895223
Expression of the receptor guanylyl cyclase C and its ligands in reproductive tissues of the rat: a potential role for a novel signaling pathway in the epididymis. PMID: 12444076
The protein kinase-like domain in receptor guanylyl cyclase C provides a critical structural link between the extracellular domain and the catalytic domain in regulation of this family of receptors. PMID: 11478887

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.